Zura Bio (NASDAQ:ZURA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Zura Bio (NASDAQ:ZURA) released its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02), Zacks reports.

Zura Bio Stock Down 1.9%

NASDAQ ZURA traded down $0.11 on Thursday, hitting $5.67. The company’s stock had a trading volume of 280,040 shares, compared to its average volume of 832,921. The company’s 50-day moving average is $4.91 and its 200 day moving average is $5.40. The firm has a market cap of $537.87 million, a PE ratio of -5.03 and a beta of -0.02. Zura Bio has a 1-year low of $1.57 and a 1-year high of $7.44.

Institutional Trading of Zura Bio

Several institutional investors have recently modified their holdings of the business. Suvretta Capital Management LLC raised its position in Zura Bio by 1.7% during the 4th quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock worth $29,171,000 after purchasing an additional 94,110 shares during the last quarter. VR Adviser LLC lifted its holdings in Zura Bio by 15.4% during the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after buying an additional 713,899 shares during the period. JPMorgan Chase & Co. grew its position in shares of Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares during the last quarter. Braidwell LP grew its position in shares of Zura Bio by 28.6% in the 4th quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock valued at $16,665,000 after buying an additional 707,583 shares during the last quarter. Finally, Affinity Asset Advisors LLC increased its stake in shares of Zura Bio by 42.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,813,671 shares of the company’s stock valued at $9,504,000 after buying an additional 539,320 shares during the period. Institutional investors own 61.14% of the company’s stock.

Analyst Upgrades and Downgrades

ZURA has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. William Blair began coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating for the company. Guggenheim increased their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. Wedbush raised their target price on shares of Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Wall Street Zen raised shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zura Bio presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.